공지사항

Esophageal canadian pacific blood cancer (EAC) and Esophageal Sarcoma (ESCC) in Canada

Since the mid-1980s, EAC rates have increased in Canada while ESCC rates have declined. These opposite trends could be due to changes in cigarette smoking, diet or other factors.

Five-year survival rate for people diagnosed with esophageal cancer is low (13 percent). The rates vary according to the morphology and the anatomic site.

Risk Factors

Esophageal cancer is a leading cause of cancer death worldwide with more than 604,000 new cases and 544,000 deaths in 2017. Around 70% of cases are male, and Canadian Pacific Acute Lymphocytic Leukemia are more common among people who are older. The incidence and Canadian Pacific Asthma mortality rates vary by region. The most severe rates are found in Eastern Asia (especially China) and the lowest are found in Western sub-Saharan Africa.

Overall, the global age-standardised incidence, mortality and DALY rates for esophageal squamous cell carcinoma (ESCC) have been decreasing since 1990; however, this trend is not consistent across all countries/territories. These changes are partly due to improved diagnosis and Canadian pacific acute lymphocytic Leukemia treatment as well as the changing environment globally, with increased exposure to smoking cigarettes and alcohol consumption.

In addition, a number of risk factors can be linked to the development of esophageal-adenocarcinoma (EAC). This includes the presence of a history of gastro-oesophageal reflux disease, long-term smoking or alcohol consumption, frequent smoking and poor oral health; a diet deficient in fruits and vegetables and being overweight. A predisposition to genetics to Barrett's Esophagus and other gastrointestinal disorders are possible risk factors.

The specific esophageal cancer-related DALY is calculated by using the incidence and prevalence rates at the country level as well as a weighting factor specific to the disease to determine the specific disability caused by sequelae. For more information, please refer to the Methodology Section of the Technical Report.

Diagnosis

The rate of incidence and survival of esophageal cancer are very low. In Canada the five-year survival rate is 13%. This is the lowest cancer-specific survival rate.

Esophageal cancers are divided into two categories: esophageal carcinomas (ESCC) or esophageal adenocarcinomas. Tumors located in the upper part of the esophagus may be classified as squamous-cell cancers, while those that are located in the lower region of the esophagus could be Adenocarcinomas. Usually there is a need for a biopsy to confirm the diagnosis. The procedure used for this is called an esophagogastroduodenoscopy. It involves passing a flexible camera-equipped tube down the throat in order to examine the esophageal walls. The biopsy is then taken from the lesion and tested for malignancy.

Since the mid-1980s, the rates of Esophageal carcinoma have been steady in Canada in Canada, with EAC rates slightly higher than ESCC. Between 1986 and 2006 the prevalence of EAC increased by two-thirds, while ESCC decreased by a third. The rise in EAC could be due to obesity and gastroesophageal reflux disease. Smoking cessation may be the cause of the decrease in ESCC.

The incidence and survival patterns vary across the country based on the morphology of the tumor and anatomical location, as well as other factors. For instance, rates of EAC have significantly increased in British Columbia and Ontario, while rates for ESCC have declined there.

Treatment

The cancer could be in the outer layer of cells (squamous cell carcinoma), or the muscle and connective tissue on the inside (esophageal squamous tumor). These types of cancers are often treated by surgery. It is more difficult for the cancer to be cured in cases where it has spread to nearby lymph nodes and tissues. People suffering from stage II esophageal cancer can be treated with endoscopic ablation or radiation therapy. They also require a close follow-up by endoscopy to check for any signs of the cancer coming back.

Chemotherapy employs drugs to kill canadian pacific pancreatic cancer cells or stop them from growing. The drugs can be consumed by mouth or canadian Pacific acute lymphocytic leukemia injected into a vein or muscle. They can be given with or without radiation. When chemotherapy is coupled with radiation the treatment is known as chemotherapy radiation.

To keep the esophagus in a closed position during radiation treatment, a plastic tube can be inserted. This is known as a gastostomy tube. It is important to keep the esophagus ajar since swallowing can in preventing pneumonia.

Targeted therapy is a method of treatment that utilizes drugs to target specific cancer cells, reducing the adverse effects of radiation therapy or chemotherapy. These medications could comprise monoclonal antibody and other medications. There are currently clinical trials underway to discover new ways to treat cancers of the esophagus.